期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

重组腺病毒介导的HBV核心蛋白和hEDN融合蛋白基因在小鼠肝脏的表达 被引量：6

Expression of fusion protein gene of HBV core protein and human eosinophil derived neurotoxin mediated by recombinant adenovirus in mouse liver
暂未订购
导出
摘要 目的 :使HBc hEDN基因重组腺病毒载体 (AdHBc hEDN)及其对照载体AdhEDN在小鼠肝脏获得表达 .方法 :将体外扩增获得的高滴度AdHBc hEDN和AdhEDN经尾静脉注射感染小鼠 ,并用免疫组化的方法检测AdHBc hEDN和Ad hEDN在小鼠肝脏中的表达 .结果 :重组腺病毒AdHBc hEDN和AdhEDN在小鼠肝脏均获得了阳性表达 .结论 :HBc AIM: To express the recombinant adenovirus vector AdHBc hEDN and the control vector AdhEDN in mouse liver respectively. METHODS: Mice were injected with high titer of AdHBc hEDN and AdhEDN via tail vein and the expressions of the two recombinant adenovirus vectors in liver were studied by immunohistochemistry. RESULTS: Both recombinant adenovirus vectors were expressed successfully in mouse liver. CONCLUSION: Expression of the recombinant adenovirus vector AdHBc hEDN lays the foundation for its anti HBV function study in HBV animal model.
作者 赵亚 刘军 宫卫东 李英辉 丁劲 薛采芳
机构地区 第四军医大学基础部病原生物学教研室
出处 《第四军医大学学报》 北大核心 2004年第12期1073-1076,共4页 Journal of the Fourth Military Medical University
基金 国家自然科学基金资助项目 (30 1 0 0 1 57) 全军医药卫生科研基金资助项目 (0 1MA1 84)
关键词 肝炎病毒 乙型 重组融合蛋白质类 腺病毒科 重组 遗传 免疫组织化学 hepatitis B virus recombinant fusion proteins adenoviridae recombination, genetic immunohistochemistry
分类号 R373.21 [医药卫生—病原生物学]
  • 相关文献

参考文献13

  • 1Natsoulis G , Boeke JD. New antiviral strategy using capsid-nuclease fusion proteins [J]. Nature, 1991; 352(6336):632-635.
  • 2李英辉,刘军,薛采芳.HBV靶向核糖核酸酶真核表达载体的构建及其在2.2.15细胞内的表达[J].细胞与分子免疫学杂志,2002,18(3):217-220. 被引量：9
  • 3赵亚,宫卫东,刘军,李英辉,丁劲,薛采芳.HBV-TR重组腺病毒载体的构建[J].第四军医大学学报,2004,25(4):321-324. 被引量：5
  • 4李立文,王臻,苏明权,马越云,于文彬,杨旻,李哲.构建由缺氧反应元件修饰的hTERT核心启动子引导FCY1基因表达的复制缺陷型腺病毒[J].第四军医大学学报,2002,23(12):1061-1064. 被引量：3
  • 5Coleman WB. Mechanisms of human hepatocarcinogenesis [J] . Curr Mol Med, 2003;3(6):573-588.
  • 6Maier KP. Hepatitis: Associated diseases. Risk groups-prevention-treatment [J]. Schweiz Rundsch Med Prax, 2003;92(33):1351-1357.
  • 7Kubba AK, Taylor P, Graneek B, et al. Non-responders to hepatitis B vaccination: A review [J]. Commun Dis Public Health, 2003;6(2):106-112.
  • 8Lagget M, Rizzetto M. Current pharmacotherapy for the treatment of chronic hepatitis B [J]. Expert Opin Pharmacother, 2003; 4(10):1821-1827.
  • 9Donna P, Philip N. Improved system for helper-dependent adenoviral vector production [J]. Mol Ther, 2003; 8(5):846-852.
  • 10Connelly S, Mech C. Delivery of adenoviral DNA to mouse liver [J]. Methods Mol Biol, 2004; 246: 37-52.

二级参考文献26

  • 1[1]Natsoulis G,Boeke JD.New antiviral strategy using capsid-nuclease fusion proteins[J].Nature,1991,352(6336):632-635.
  • 2[2]Sambrook J,Fritsch EF,Maniatis T,et al.Molecular Cloning,a Laboratory Manmual[M],2nd ed,Cold Spring Harbor laboratory.Cold Spring Harbor,New York:1989:880-898.
  • 3[3]Chumann G,Qin L,Rein A,et al.Therapeutic effect of gag-nuclease fusion protein on retrovirus-infected cell cultures[J].J Virol,1996,70(7):4329-4337.
  • 4[4]Chumann G,Cannon K,Ma WP,et al.Antiretroviral effect of a gag-Rnase HI fusion gene[J].Gene Ther,1997,4(6):593-599.
  • 5[5]Elekhovets YF,Joshi S.Fusion with an RNA binding domain to confer target RNA specificity to an RNase:design and engineering of Tat-RNase H that specigically recognizes and cleaves HIV-1 RNA in vitro[J].Nucleic Acids Res,1996,24(10)1908-1912.
  • 6[6]Unker-Niepmann M,Bartenschlager R,Schaller H.A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA[J].EMBO J,1990,9(10):3389-3396.
  • 7[1]Harrington KJ, Linardakis E, Vile RG. Transriptional control: An essential component of cancer gene therapy strategies [J]? Adv Drug Deliv Rev, 2000;44(1-2):167-184.
  • 8[2]Nettelbeck DM, Jerome V, Luller R. Gene therapy: Designer promoters for tumor targeting [J]. Trends Genet, 2000;16(4):174-181.
  • 9[3]Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg A. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells [J]. Mol Ther, 2000;2(6):539-544.
  • 10[4]Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP. The telemerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters [J]. Gene Ther, 2001;8(7):568-578.

共引文献13

同被引文献39

引证文献6

二级引证文献4

第四军医大学学报
2004年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部